nContact was founded in June 2005 by Jim Whayne and Sid Fleischman, who hold more than 100 patents in ablation technologies and helped develop the first surgical and catheter ablation tools for AF treatment. They started nContact because catheter and surgical ablation companies had not solved two technical issues: the ability to consistently create visible linear lesions, and the ability to position and ablate on the posterior of the atrium under direct visibility.

The primary goal in founding nContact was to develop technology and access capability to perform truly minimally invasive ablation procedures on a beating heart without chest incisions or ports.

The nContact device has received clearance from the United States Food and Drug Administration (FDA) to coagulate cardiac tissue during endoscopic procedures. The FDA has not approved or cleared these devices for the treatment of specific arrhythmias. nContact has approved IDEs to enroll patients in clinical trials for the treatment of AF.